The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes in large B-cell lymphoma progressing after axicabtagene ciloleucel (Axi-cel): Results from the U.S. Lymphoma CAR-T Consortium.
 
Jay Y. Spiegel
No Relationships to Disclose
 
Saurabh Dahiya
No Relationships to Disclose
 
Michael D. Jain
Consulting or Advisory Role - Kite/Gilead
Travel, Accommodations, Expenses - Kite/Gilead
 
Loretta J. Nastoupil
Honoraria - Bayer; Celgene; Gilead Sciences; Janssen Oncology; Novartis; Spectrum Pharmaceuticals
Research Funding - Celgene; Genentech/Roche; Janssen Biotech; Karus Therapeutics; LAM Therapeutics; TG Therapeutics
 
Armin Ghobadi
Consulting or Advisory Role - Amgen; Celgene; Kite/Gilead
Speakers' Bureau - Kite/Gilead
Research Funding - Kite/Gilead
 
Yi Lin
Research Funding - Bluebird Bio; Celgene; Janssen; Kite, a Gilead company; Merck; Takeda
 
Matthew Alexander Lunning
Consulting or Advisory Role - Abbvie; Bayer; Celgene; Genentech; Genzyme; Gilead Sciences; Janssen Oncology; Juno Therapeutics; Kite, a Gilead company; Novartis; Pharmacyclics; Portola Pharmaceuticals; Seagen; Spectrum Pharmaceuticals; TG Therapeutics; Verastem
Research Funding - Celgene (Inst); Celgene (Inst); Celgene (Inst); Curis (Inst); Janssen Oncology (Inst); Juno Therapeutics (Inst); Juno Therapeutics (Inst); miRagen (Inst); TG Therapeutics (Inst); TG Therapeutics (Inst)
 
Patrick Michael Reagan
Research Funding - Seagen
 
Joseph McGuirk
Honoraria - Kite, a Gilead company; Novartis
Consulting or Advisory Role - Kite, a Gilead company
Speakers' Bureau - Kite/Gilead
Research Funding - Astellas Pharma (Inst); Bellicum Pharmaceuticals (Inst); Fresenius Biotech (Inst); Gamida Cell (Inst); Kite, a Gilead company (Inst); Novartis (Inst); Novartis (Inst); Pluristem Therapeutics (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company
 
Abhinav Deol
Consulting or Advisory Role - Agios; Kite/Gilead; Novartis
 
Javier Munoz
Consulting or Advisory Role - Alexion Pharmaceuticals; Bayer; Bristol-Myers Squibb; Celgene; Genentech; Gilead Sciences; Janssen; Juno Therapeutics; Kite, a Gilead company; Kyowa Hakko Kirin; Pfizer; Pharmacyclics; Seagen
Speakers' Bureau - AstraZeneca; Bayer; Gilead Sciences; Kite, a Gilead company; Pharmacyclics/Janssen
 
Frederick Lundry Locke
Consulting or Advisory Role - Cellular Biomedicine Group; Kite, a Gilead company
 
Sattva Swarup Neelapu
Honoraria - Bio Ascend; Dava Oncology; Medscape; Physicans' Education Resource
Consulting or Advisory Role - Celgene; Cell Medica; Gilead Sciences; Incyte; Kite, a Gilead company; Merck Sharp & Dohme; Novartis; Pfizer; Precision Biosciences; Unum Therapeutics
Research Funding - Acerta Pharma; Bristol-Myers Squibb; Celgene; Cellectis; Gilead Sciences; Karus Therapeutics; Kite, a Gilead company; Merck Sharp & Dohme; Pharmacyclics; poseida therapeutics; Unum Therapeutics
Travel, Accommodations, Expenses - Celgene; Chugai Pharma; Dava Oncology; Kite/Gilead; Medscape; Merck; Novartis; Pfizer; Physicans' Education Resource; Precision Biosciences; Unum Therapeutics
 
John S Tamaresis
No Relationships to Disclose
 
Aaron Rapoport
No Relationships to Disclose
 
David Bernard Miklos
Honoraria - Sanofi; Sanofi
Consulting or Advisory Role - Adaptive Biotechnologies; Janssen; Janssen; Janssen; Juno/Celgene; Kite, a Gilead company; Novartis; Pharmacyclics
Research Funding - Adaptive Biotechnologies; Adaptive Biotechnologies; Kite, a Gilead company; Novartis; Pharmacyclics; Roche/Genentech
Patents, Royalties, Other Intellectual Property - Patent held with Pharmacyclics supporting Ibrutinib for cGVHD (no royalty claim)
Travel, Accommodations, Expenses - Adaptive Biotechnologies; Juno Therapeutics; Kite, a Gilead company; Pharmacyclics/Janssen; Sanofi
 
Brian Thomas Hill
Honoraria - Abbvie; Bayer; Genentech; Gilead Sciences; Pharmacyclics; Seagen
Consulting or Advisory Role - Abbvie/Genentech; Novartis; Seagen
Research Funding - Abbvie (Inst); Amgen (Inst); Celgene (Inst); Karyopharm Therapeutics (Inst); Takeda (Inst)